Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Discovery of selective irreversible inhibitors for EGFR-T790M.

Bioorganic & medicinal chemistry letters - 15 Jan 2011

Zhou Wenjun, Ercan Dalia, Jänne Pasi A, Gray Nathanael S

Abstract excerpt

Targeting the epidermal growth factor receptor kinase (EGFR) with ATP-competitive kinase inhibitors results in dramatic but short-lived responses in patients with EGFR mutant non small cell lung cancer. A series of novel covalent EGFR kinase inhibitors with selectivity for the clinically relevant T790M 'gatekeeper' resistance mutation relative to wild-type EGFR were discovered by library screening. A...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Carcinoma, Non-Small-Cell Lung
Share to Cell Proliferation

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to ErbB Receptors

Share to Protein Kinase Inhibitors

Share to Small Molecule Libraries

Share to Structure-Activity Relationship

Source

Open in PubMed Open full text

Identifiers

PMID: 21208802
DOI: 10.1016/j.bmcl.2010.12.036
PMCID: PMC3035422

Genes

EGFR

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Discovery of selective irreversible inhibitors for EGFR-T790M.PMID 21208802Read ↗

Novel mutant-selective EGFR kinase inhibitors against EGFR T790M.Semantic proximity Read ↗

Chemogenomic profiling provides insights into the limited activity of irreversible EGFR Inhibitors in tumor cells expressing the T790M EGFR resistance mutation.Semantic proximity Read ↗

Indazole-Based Covalent Inhibitors To Target Drug-Resistant Epidermal Growth Factor Receptor.Semantic proximity Read ↗

Noncovalent wild-type-sparing inhibitors of EGFR T790M.Semantic proximity Read ↗

Chemical Scaffolds for the Clinical Development of Mutant-Selective and Reversible Fourth-Generation EGFR-TKIs in NSCLC.Semantic proximity Read ↗

Discovery of pteridin-7(8H)-one-based irreversible inhibitors targeting the epidermal growth factor receptor (EGFR) kinase T790M/L858R mutant.Semantic proximity Read ↗

Structure-based design and synthesis of covalent-reversible inhibitors to overcome drug resistance in EGFR.Semantic proximity Read ↗

Discovery and optimization of covalent EGFR T790M/L858R mutant inhibitors.Semantic proximity Read ↗

Discovery of novel selective inhibitors for EGFR-T790M/L858R.Semantic proximity Read ↗

Discovery of a Noncovalent, Mutant-Selective Epidermal Growth Factor Receptor Inhibitor.Semantic proximity Read ↗

Discovery of 1-{(3R,4R)-3-[({5-Chloro-2-[(1-methyl-1H-pyrazol-4-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}oxy)methyl]-4-methoxypyrrolidin-1-yl}prop-2-en-1-one (PF-06459988), a Potent, WT Sparing, Irreversible Inhibitor of T790M-Containing EGFR Mutants.Semantic proximity Read ↗

Design, synthesis, and biological evaluation of novel conformationally constrained inhibitors targeting epidermal growth factor receptor threonine⁷⁹⁰ → methionine⁷⁹⁰ mutant.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.